Document Type : Original Article
Department of Oncology, Yanbian University Hospital (Yanbian hospital), Yanji, China
Department of Hepatobiliary Surgery, Yanbian University Hospital (Yanbian hospital), Yanji, China
The aim of this study is to elucidate the role of PRDX1 in hepatocellular carcinoma using hepatoma
Materials and Methods
In this experimental study, we elucidated role of PRDX1, using hepatoma cell lines.
PRDX1 was upregulated in different types of cancers, including lung adenocarcinoma, breast cancer and liver
cancer reported by several studies. nevertheless, mechanism of inducing liver cell death by PRDX1 remains largely
unknown. Here, we showed that PRDX1 expression is enhanced in different cell lines. Here, we used western blot,
quantitative real time polymerase chain reaction (qRT-PCR) and different biochemical assays to explore the role of
PRDX1. We observed that overexpression of PRDX1 significantly enhanced proliferation of hepatoma cell lines, while
knock-down of this gene showed significant inhibitory effects. We found that knock-down of PRDX1 activated cleaved
caspase-3, caspase-9 proteins and Poly [ADP-ribose] polymerase 1 (PARP-1), which further executed apoptotic
process, leading to cell death. We found that PRDX1 knock-down significantly produced mitochondrial fragmentation.
We showed that silencing PRDX1 led to the loss of B-cell lymphoma 2 (Bcl-2) and activated Bcl-2-like protein 11 (Bim)
which further induced Bax activation. Bax further released cytochrome c from mitochondria and induced apoptotic
proteins, suggesting a significant role of PRDX1 knock-down in apoptosis. Finally, we showed that knock-down of
PRDX1 significantly activated expression of Dynein-related protein 1 (Drp1), fission 1 (Fis1) and dynamin-2 (Dyn2)
suggesting a crucial role of PRDX1 in mitochondrial fragmentation and apoptosis conditions. This study highlighted an
important role of PRDX1 in regulating proliferation of hepatoma cells and thus future studies are required to validate its
effect on hepatcoytes.
We propose that future works on PRDX1 inhibitors may act as a therapeutic candidate for treatment of liver cancer.